Please assess the completion status of the following clinical trial:

Trial Title: Long Term Study of RBP 7000 in the Treatment of Subjects With Schizophrenia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~De Novo Patients~* Diagnosis of schizophrenia as defined by Diagnostic and Statistical Manual, Edition 4, text revision (DSM-IV-TR) criteria~* Total PANSS score \<=70 at the time of screening (Visit 1)~* Otherwise healthy on the basis of physical examinatIon~* Provided written informed consent~Roll-over Patients~* Provided written consent to participate in this study~* Be considered eligible to enroll based on End of Study (EOS) (Day 57 of Study RB-US-09-0010) assessments and the medical judgment of the investigator~Exclusion Criteria:~De Novo Patients~* Patients taking daily oral risperidone at a dose plus/minus 6 mg/day~* Patients taking any risperidone or 9-hydroxyrisperidone long-acting injectable formulation within 120 days of study screening (Visit 1)~* Patients who have received a long-acting injectable antipsychotic within 120 days of screening (Visit 1)~* Patients with evidence or history (in the past six months prior to screening) of a significant hepatic disorder that may either compromise patient safety or interfere with the safety and/or outcome evaluation of the study drug, including:~  * Acute or chronic hepatitis, including but not limited to hepatitis B or C~ * Total bilirubin greater than 1.5 times the upper limit of normal (ULN), or~ * Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) greater than 2 times ULN~* Patients with a history of drug-induced leukopenia~* Patients with other medical conditions including, but not limited to, history of heart attack (myocardial infarction) or brain injury (traumatic injury with loss of consciousness and/or cerebrovascular accident), and clinically significant low blood pressure or arrhythmias as interpreted by the primary investigator (PI) or medically qualified sub-investigator~* Patients with epilepsy or other seizure disorders, Parkinson's disease or dementia~Roll-over Patients~* Patients requiring an inpatient treatment setting at the end of Study RB-US-09-0010~* Patients with an unstable medical condition developed during Study RB-US-09-0010~* Women of childbearing potential who have a positive pregnancy test at screening (Visit 1), who are pregnant or breastfeeding, seeking pregnancy, or failing to use adequate contraceptive methods during the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- RBP-7000 - 120-mg dose (Type: EXPERIMENTAL): RBP-7000 120-mg subcutaneous (SC) injections every 28 days for 13 doses as open-label therapy. Patients enter the study as 'roll-over' patients from study RB-US-09-0010, or de novo patients. Pre-study procedures vary for de novo patients depending on previous therapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete